What it's for (Indications)
- Gestodene + ethinylestradiol is primarily indicated for the prevention of pregnancy (contraception).
- It works as a highly effective combined oral contraceptive by inhibiting ovulation, altering cervical mucus, and modifying the endometrium to prevent implantation.
- Beyond its primary contraceptive role, this medication may also be prescribed for managing conditions such as dysmenorrhea (painful menstruation), irregular menstrual cycles, and in some cases, for the symptomatic treatment of acne vulgaris in women seeking contraception.
- The decision to prescribe for these secondary indications is typically made after careful consideration of individual patient needs, potential benefits, and a thorough assessment of associated risks, adhering to current clinical guidelines.
Dosage Information
| Type | Guideline |
|---|---|
| Standard | The standard dosage regimen for gestodene + ethinylestradiol, such as in Meliane, typically involves taking one active tablet daily for 21 consecutive days, followed by a 7-day tablet-free interval or the consumption of 7 placebo tablets, during which withdrawal bleeding usually occurs. This 28-day cycle is then repeated. For initial initiation, administration commonly begins on the first day of the menstrual period (Day 1 start) or on the first Sunday following the commencement of menses (Sunday start), depending on clinical guidance and patient preference. Consistent daily intake at approximately the same time is crucial for maximizing contraceptive efficacy. Missed doses require specific patient counseling based on the duration and timing of the omission to maintain contraceptive protection and prevent unintended pregnancy. |
Safety & Warnings
Common Side Effects
- Commonly reported side effects associated with gestodene + ethinylestradiol include nausea, vomiting, headache, breast tenderness or pain, weight changes (gain or loss), mood alterations (including depression), and breakthrough bleeding or spotting, particularly during the initial cycles of use.
- These symptoms often diminish with continued use as the body adjusts to the hormones.
- More serious, albeit less frequent, adverse events encompass an increased risk of venous thromboembolism (VTE), arterial thrombotic events (e.
- g.
- , myocardial infarction, stroke), hypertension, gallbladder disease, hepatic adenomas or hepatocellular carcinoma, and exacerbation of pre-existing conditions like migraine.
- Patients should be advised to seek immediate medical attention if they experience symptoms indicative of serious adverse effects, such as sudden severe headache, chest pain, vision changes, or leg swelling.
Serious Warnings
- Black Box Warning: Cigarette smoking increases the risk of serious cardiovascular events from combined oral contraceptive (COC) use. This risk increases with age, particularly in women over 35 years, and with the amount of smoking. For this reason, COCs, including gestodene + ethinylestradiol, are contraindicated in women who are over 35 years of age and smoke. Other serious cardiovascular risks associated with COC use include an elevated risk of venous thromboembolism (VTE), arterial thrombotic events such as myocardial infarction and stroke, especially in individuals with pre-existing risk factors like hypertension, hyperlipidemia, or a family history of thrombotic disorders. Patients should be thoroughly counseled on these risks, and smoking cessation should be strongly recommended to mitigate potential life-threatening complications.
- Patients utilizing gestodene + ethinylestradiol should be thoroughly counseled on critical warnings prior to initiation and throughout therapy.
- Foremost among these is the significantly increased risk of serious cardiovascular events, including thrombosis, myocardial infarction, and stroke, particularly in women who smoke and are over 35 years of age.
- Smoking cessation is strongly advised.
- Regular blood pressure monitoring is essential, as combined oral contraceptives can cause an increase in blood pressure.
- Glucose tolerance may be impaired, necessitating careful monitoring in diabetic patients.
- Women with a history of depression should be observed for mood changes, and the medication should be discontinued if severe depression recurs.
- The risk of developing liver tumors, though rare, is also a consideration.
- Any unexplained vaginal bleeding should be investigated to rule out malignancy, and surgical procedures or prolonged immobilization may necessitate temporary discontinuation due to increased VTE risk.
How it Works (Mechanism of Action)
Gestodene + ethinylestradiol exerts its primary contraceptive effect through several interconnected mechanisms. The synthetic estrogen, ethinylestradiol, and the progestin, gestodene, work synergistically to suppress the hypothalamic-pituitary-ovarian (HPO) axis. This suppression primarily inhibits the release of gonadotropins, namely Luteinizing Hormone (LH) and Follicle-Stimulating Hormone (FSH), which in turn prevents ovarian follicular development and ovulation. Additionally, the progestin component, gestodene, contributes significantly by thickening cervical mucus, rendering it impenetrable to sperm, and by inducing endometrial changes that make the uterus inhospitable for implantation of a fertilized egg. These combined actions provide highly effective contraception when used consistently and correctly.
Commercial Brands (Alternatives)
No other brands found for this formula.